Lastly, due to the specific overexpression/up-regulation of NET in certain neuroendocrine tumors, radiolabeled compounds could also be used for chemotherapy, as seen with the use of currently the only clinically utilized NET ligand, 123/131I-meta-iodobenzylguanidine (123/131I-MIBG), against neuroendocrine tumors. This evidence concerns the gene SLC6A2 and neuroendocrine neoplasm.